scholarly journals Rapamycin modulates pulmonary pathology in a Murine model of Mycobacterium tuberculosis infection

Author(s):  
Kamlesh Bhatt ◽  
Madhuri Bhagavathula ◽  
Sheetal Verma ◽  
Graham S. Timmins ◽  
Vojo P. Deretic ◽  
...  

In this study we employed C3HeB/FeJ mice as an experimental model to investigate the potential role of rapamycin, an mTOR inhibitor, as an adjunctive therapy candidate during the treatment of Mycobacterium tuberculosis infection with moxifloxacin. We report that administration of rapamycin with or without moxifloxacin reduced infection-induced lung inflammation, and the number and size of caseating necrotic granulomas. Results from this study strengthen the potential use of rapamycin and its analogs as adjunct TB therapy and importantly underscore the utility of the C3HeB/FeJ mouse model as a pre-clinical tool to evaluate HDT candidates in TB treatment.

2018 ◽  
Vol 219 (10) ◽  
pp. 1662-1670 ◽  
Author(s):  
Valerie A C M Koeken ◽  
Ekta Lachmandas ◽  
Anca Riza ◽  
Vasiliki Matzaraki ◽  
Yang Li ◽  
...  

2012 ◽  
Vol 206 (12) ◽  
pp. 1816-1825 ◽  
Author(s):  
V. Kaul ◽  
D. Bhattacharya ◽  
Y. Singh ◽  
L. Van Kaer ◽  
M. Peters-Golden ◽  
...  

Author(s):  
Pasquale Comberiati ◽  
Maria Di Cicco ◽  
Francesco Paravati ◽  
Umberto Pelosi ◽  
Alessandro Di Gangi ◽  
...  

Tuberculosis is one of the most common infectious diseases and infectious causes of death worldwide. Over the last decades, significant research effort has been directed towards defining the understanding of the pathogenesis of tuberculosis to improve diagnosis and therapeutic options. Emerging scientific evidence indicates a possible role of the human microbiota in the pathophysiology of tuberculosis, response to therapy, clinical outcomes, and post-treatment outcomes. Although human studies on the role of the microbiota in tuberculosis are limited, published data in recent years, both from experimental and clinical studies, suggest that a better understanding of the gut–lung microbiome axis and microbiome–immune crosstalk could shed light on the specific pathogenetic mechanisms of Mycobacterium tuberculosis infection and identify new therapeutic targets. In this review, we address the current knowledge of the host immune responses against Mycobacterium tuberculosis infection, the emerging evidence on how gut and lung microbiota can modulate susceptibility to tuberculosis, the available studies on the possible use of probiotic–antibiotic combination therapy for the treatment of tuberculosis, and the knowledge gaps and future research priorities in this field.


1997 ◽  
Vol 56 ◽  
pp. 444
Author(s):  
G. Mancino ◽  
R. Placido ◽  
R. Cicconi ◽  
V. Colizzi ◽  
F. Di Virgilio ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document